March 31 (Reuters) - Kairos Pharma Ltd KAPA.A:
KAIROS PHARMA LTD. ANNOUNCES COMPLETED ENROLLMENT OF THE SAFETY ARM OF ITS PHASE 2 CLINICAL TRIAL OF ENV105 IN METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER
KAIROS PHARMA LTD - SAFETY AND EFFICACY DATA READOUT EXPECTED IN FIRST HALF OF 2025
Source text: ID:nBw5qrQnva
Further company coverage: KAPA.A
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.